as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹2,906.1
Change
+11.2 (0.39%)
Open
₹2,975.5
Prev. Close
₹2,894.9
Day High
₹2,980.0
Day Low
₹2,844.3
Volume Analysis
Traded
6,224
Delivered
1,958
Delivery %
31.46%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (32.9%)
- •Strong 3-year revenue growth (21.7%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,111.66 | ₹3,045.83 | ₹2,975.96 | ₹2,910.13 | ₹2,840.26 | ₹2,774.43 | ₹2,704.56 |
| Fibonacci | ₹3,045.83 | ₹2,993.99 | ₹2,961.97 | ₹2,910.13 | ₹2,858.29 | ₹2,826.27 | ₹2,774.43 |
| Camarilla | ₹2,943.42 | ₹2,930.98 | ₹2,918.54 | ₹2,910.13 | ₹2,893.66 | ₹2,881.22 | ₹2,868.78 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+108.08%
1 Week
+6.39%
1 Month
+3.29%
3 Months
-6.48%
6 Months
+39.64%
1 Year
+109.3%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹966.61
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
16.23%
Net margin 10.63% × asset turnover 0.92x × equity multiplier 1.66x
Company Overview
Sector
Healthcare
Market Cap
₹1,796 Cr
P/E (TTM)
31.4
ROE
17.4%
Book Value
₹533.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Ngl Fine Chem Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 54/100. The strongest factor is Financial Strength (96/100), while Liquidity (15/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. Strong 3-year EPS growth (32.9%).
TopFund Score — Fundamentals Quality
54/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
GST department issues show cause notice for ₹6.19 crore demand for FY23.
Phase II of Tarapur greenfield facility commenced commercial production on Sept. 24, 2026; total investment ₹222 crore.
One-on-one virtual analyst/investor meet held on September 16, 2026; no presentation and no UPSI shared.
A One to One meet has been scheduled on Wednesday, September 16, 2026 with Analyst/Investor.
45th AGM held on August 25, 2026; all resolutions passed with requisite majority.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 71 | 80 | 88 | 100 | 91 | 93 | 89 | 95 | 104 | 120 | 128 | 149 | 139 |
| Expenses + | 61 | 66 | 74 | 84 | 81 | 82 | 84 | 89 | 93 | 103 | 105 | 128 | 116 |
| Operating Profit | 10 | 14 | 14 | 16 | 9 | 12 | 5 | 6 | 11 | 17 | 22 | 21 | 23 |
| OPM % | 14.0% | 17.0% | 16.0% | 16.0% | 10.0% | 12.0% | 6.0% | 7.0% | 11.0% | 14.0% | 18.0% | 14.0% | 17.0% |
| Other Income + | 3 | 3 | 4 | 4 | 6 | 5 | 0 | -1 | 6 | 2 | 5 | 2 | 7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 5 |
| Profit before tax | 10 | 14 | 14 | 16 | 12 | 13 | 1 | 1 | 12 | 13 | 21 | 18 | 24 |
| Tax % | 16.0% | 25.0% | 30.0% | 23.0% | 22.0% | 26.0% | -1.0% | 49.0% | 22.0% | 26.0% | 24.0% | 24.0% | 25.0% |
| Net Profit + | 9 | 10 | 10 | 12 | 9 | 10 | 1 | 1 | 9 | 10 | 16 | 13 | 18 |
| EPS in Rs | 14 | 17 | 16 | 20 | 15 | 16 | 2 | 1 | 15 | 16 | 25 | 22 | 30 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 153 | 152 | 258 | 318 | 278 | 339 | 368 | 501 | 536 |
| Expenses + | 121 | 130 | 178 | 249 | 243 | 285 | 333 | 421 | 452 |
| Operating Profit | 32 | 22 | 80 | 68 | 35 | 54 | 35 | 80 | 84 |
| OPM % | 21.0% | 14.0% | 31.0% | 21.0% | 13.0% | 16.0% | 10.0% | 16.0% | 16.0% |
| Other Income + | 4 | 1 | 8 | 11 | 6 | 14 | 8 | 8 | 17 |
| Interest | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 5 | 4 |
| Depreciation | 6 | 8 | 8 | 10 | 11 | 12 | 12 | 20 | 21 |
| Profit before tax | 28 | 12 | 78 | 67 | 27 | 54 | 28 | 63 | 76 |
| Tax % | 27.0% | 31.0% | 27.0% | 25.0% | 25.0% | 24.0% | 24.0% | 24.0% | — |
| Net Profit + | 20 | 8 | 57 | 50 | 20 | 41 | 21 | 48 | 57 |
| EPS in Rs | 33 | 14 | 92 | 81 | 33 | 67 | 34 | 78 | 93 |
| Dividend Payout % | 5.0% | 13.0% | 2.0% | 2.0% | 5.0% | 3.0% | 5.0% | 2.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 89 | 96 | 151 | 200 | 219 | 260 | 279 | 326 |
| Borrowings + | 27 | 28 | 16 | 30 | 32 | 34 | 78 | 123 |
| Other Liabilities + | 23 | 26 | 36 | 44 | 32 | 59 | 75 | 94 |
| Total Liabilities | 142 | 154 | 207 | 277 | 287 | 356 | 435 | 545 |
| Fixed Assets + | 61 | 68 | 64 | 89 | 88 | 86 | 143 | 164 |
| CWIP | 0 | 0 | 12 | 6 | 26 | 46 | 50 | 95 |
| Investments | 9 | 11 | 29 | 29 | 39 | 54 | 60 | 39 |
| Other Assets + | 73 | 75 | 102 | 153 | 133 | 171 | 183 | 247 |
| Total Assets | 142 | 154 | 207 | 277 | 287 | 356 | 435 | 545 |
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 9 | 20 | 27 | 14 | 35 | 20 | 32 | 43 |
| Cash from Investing Activity + | -10 | -20 | -25 | -14 | -27 | -27 | -70 | -71 |
| Cash from Financing Activity + | 0 | -1 | -1 | -1 | -1 | -1 | 37 | 30 |
| Net Cash Flow | -1 | 0 | 2 | -1 | 7 | -7 | 0 | 2 |
| CFO/OP | 50 | 110 | 60 | 45 | 121 | 62 | 111 | 73 |
| Free Cash Flow | -6 | 6 | 10 | -15 | 5 | -8 | -41 | -43 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 26.93% | 26.91% | 27.16% | 27.24% | 27.25% | 27.23% | 27.26% | 27.26% | 27.26% | 27.26% | 27.23% | 27.43% |
| Promoters | 73.06% | 73.06% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.73% | 72.49% |
| FII | 0.02% | 0.04% | 0.1% | 0.03% | 0.02% | 0.05% | 0.0% | 0.0% | 0.0% | 0.0% | 0.03% | 0.05% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.02% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Ngl Fine Chem Limited (this stock) | 1,796 | 31.4 | 5.45 | 17.4% |
| Suraksha Diagnostic Ltd | 1,788 | 49.9 | 7.3 | 14.2% |
| Krsnaa Diagnostics Ltd | 1,785 | 18.3 | 1.81 | 10.9% |
| Tarsons Products Limited | 1,770 | 150.0 | 2.8 | 2.44% |
| Hester Biosciences Ltd | 1,884 | 35.5 | 5.24 | 15.9% |
| Syncom Formu (i) Ltd | 1,885 | 22.0 | 4.54 | 17.6% |
| Anlon Healthcare Limited | 1,655 | 52.3 | 7.18 | 18.4% |
Which Mutual Funds Hold Ngl Fine Chem Limited?
Frequently Asked Questions about Ngl Fine Chem Limited
Ngl Fine Chem Limited (NGLFINE) closed at ₹2,906.1 on NSE on 25 September 2026, up 11.2 (0.39%) from the previous close.
Ngl Fine Chem Limited trades on the NSE (National Stock Exchange of India) under the symbol NGLFINE.
Ngl Fine Chem Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 31.4.
Ngl Fine Chem Limited has a dividend yield of 0.06%.
Ngl Fine Chem Limited's 52-week high is ₹3,602.0 and its 52-week low is ₹1,261.0.
Ngl Fine Chem Limited has a market capitalisation of ₹1,796 crore.
Ngl Fine Chem Limited has a TopFund Quality Score of 54/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Ngl Fine Chem Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.